Daniel Geoffrey Tenen, M.D.
Co-Author
This page shows the publications co-authored by Daniel Tenen and Susumu Kobayashi.
Connection Strength
2.279
-
Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021 Oct 14; 138(15):1331-1344.
Score: 0.247
-
Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation. Bioorg Med Chem Lett. 2019 08 15; 29(16):2286-2289.
Score: 0.211
-
Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPa. Molecules. 2018 Aug 03; 23(8).
Score: 0.198
-
ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPa. J Biol Chem. 2017 11 17; 292(46):18924-18936.
Score: 0.186
-
A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation. J Biomol Screen. 2015 Oct; 20(9):1150-9.
Score: 0.160
-
CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells. Development. 2010 Jul; 137(13):2147-56.
Score: 0.113
-
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 2010 Apr 08; 115(14):2901-9.
Score: 0.110
-
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 01; 14(21):7060-7.
Score: 0.101
-
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol. 2008 Mar 01; 26(7):1182-4; author reply 1184-6.
Score: 0.096
-
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007 Oct; 4(10):1669-79; discussion 1680.
Score: 0.094
-
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest. 2007 Sep; 117(9):2611-20.
Score: 0.093
-
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 2007 Nov 15; 110(10):3695-705.
Score: 0.092
-
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006 Dec 01; 66(23):11389-98.
Score: 0.088
-
Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci U S A. 2006 Apr 18; 103(16):6338-43.
Score: 0.084
-
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15; 65(16):7096-101.
Score: 0.081
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24; 352(8):786-92.
Score: 0.078
-
Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer. 2012 Jul; 77(1):31-7.
Score: 0.032
-
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul; 5(7):1048-53.
Score: 0.028
-
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009 May 15; 15(10):3484-94.
Score: 0.026
-
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008 Jul 15; 68(14):5827-38.
Score: 0.025
-
Phosphorylation of CCAAT/enhancer-binding protein alpha regulates GLUT4 expression and glucose transport in adipocytes. J Biol Chem. 2008 Jun 27; 283(26):18002-11.
Score: 0.024
-
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res. 2007 Nov 01; 67(21):10417-27.
Score: 0.024
-
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007 Oct; 58(1):95-103.
Score: 0.023
-
Three-dimensional magnetic resonance microscopy of pulmonary solitary tumors in transgenic mice. Magn Reson Med. 2006 Sep; 56(3):698-703.
Score: 0.022
-
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun; 9(6):485-95.
Score: 0.021
-
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005 Aug 17; 97(16):1185-94.
Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.